Gelonghui, April 22丨Zhongguancun (000931.SZ) announced that Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter: Beijing Huasu), a subsidiary of Beijing Zhongguancun Science and Technology Development (Holdings) Co., Ltd. (hereinafter referred to as the Company), recently passed the technical review by the Drug Evaluation Center of the State Drug Administration (CDE) and obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration).
Bifonazole raw materials are indicated for antifungal infections. Bifonazole (Bifonazole) was developed by Bayer in Germany. It was first marketed in Germany in 1983, then marketed for use in Japan, France, England, Italy, and Belgium. Currently, according to the CDE original and auxiliary package registration information platform, there are a total of 5 bifonazole APIs. 4 are in “A” status, and 1 is in “I” status. Beijing Huasu is the fourth company to switch to “A”. According to the National Drug Administration's drug information search, there are 63 pharmaceutical approvals for bifonazole. According to the drug dosage data of the PharmacoIntelligence Network, the average dosage of bifonazole in the past 6 years is about 3 tons.